MedCity News January 20, 2026
Rapt Therapeutics brings to GSK ozureprubart, a long-acting antibody that inhibits the validated immunology target immunoglobulin E (IgE). If GSK is able to bring this drug to the market, it would complete with the blockbuster Genentech and Novartis allergy drug Xolair.
GSK’s presence in immunology and inflammation is heavily oriented around respiratory drugs, but the company been expanding its scope through business deals. The pharmaceutical giant is now adding food allergy through the $2.2 billion acquisition of Rapt Therapeutics, a biotech whose lead program offers potential dosing and efficacy advantages over a blockbuster product marketed by two of GSK’s big pharma peers.
According to financial terms announced Tuesday, GSK will pay $58 in cash for each share of Rapt, which...
Today's Sponsors
Today's Sponsor